by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
by Elec23 | Apr 9, 2025 | News&events
VisMederi’s R&D Department, in collaboration with the University of Siena, University of Palermo, and University of Bari, has developed and validated a new high-throughput neutralization assay for human Metapneumovirus (hMPV) A and B. This pivotal work aims to...
by Elec23 | Feb 24, 2025 | News&events
VisMederi has expanded its testing portfolio with cutting-edge pseudo-viral platforms, which are critical tools for examining immunogenicity and developing vaccines against emerging infections. These new technologies enable us to test immune responses in a safe and...
by Elec23 | Sep 24, 2024 | News&events
Fondazione VisMederi has signed an agreement with Trialect Inc., USA, for the program entitled “Trialect Global Medical Education Program.” This initiative aims to provide short-term training and education for biomedical scientists and physicians to enhance the...
